Annexon, Inc. (NASDAQ:ANNX) CEO Douglas Love sold 3,750 shares of Annexon stock in a transaction dated Monday, June 7th. The shares were sold at an average price of $22.31, for a total value of $83,662.50. Following the transaction, the chief executive officer now owns 3,750 shares in the company, valued at approximately $83,662.50. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Douglas Love also recently made the following trade(s):
- On Thursday, April 1st, Douglas Love sold 500 shares of Annexon stock. The shares were sold at an average price of $28.08, for a total transaction of $14,040.00.
- On Monday, March 29th, Douglas Love sold 3,750 shares of Annexon stock. The shares were sold at an average price of $25.42, for a total transaction of $95,325.00.
Annexon stock opened at $22.84 on Friday. The company has a market cap of $873.84 million and a price-to-earnings ratio of -0.74. Annexon, Inc. has a one year low of $15.33 and a one year high of $38.01. The business’s fifty day moving average is $21.76.
Separately, Zacks Investment Research lowered shares of Annexon from a “hold” rating to a “sell” rating in a research note on Monday, March 29th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $34.33.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. E Fund Management Co. Ltd. acquired a new position in Annexon during the first quarter valued at approximately $27,000. Royal Bank of Canada lifted its position in shares of Annexon by 484.7% during the 1st quarter. Royal Bank of Canada now owns 2,216 shares of the company’s stock worth $62,000 after buying an additional 1,837 shares during the last quarter. Citigroup Inc. grew its position in Annexon by 505.9% in the fourth quarter. Citigroup Inc. now owns 4,290 shares of the company’s stock valued at $107,000 after acquiring an additional 3,582 shares during the last quarter. SG Americas Securities LLC acquired a new position in Annexon during the first quarter worth about $154,000. Finally, JPMorgan Chase & Co. boosted its stake in shares of Annexon by 27.6% in the 4th quarter. JPMorgan Chase & Co. now owns 7,013 shares of the company’s stock valued at $175,000 after purchasing an additional 1,517 shares in the last quarter. Institutional investors and hedge funds own 97.83% of the company’s stock.
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration.
See Also: How Does the Quiet Period Work?
Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.